Saccharomyces boulardii - 60 CT

Saccharomyces boulardii - 60 CT is a gastrointestinal health supplement designed by Ortho Molecular Products.* It contains 5 billion CFUs of probiotic yeast, so it may help you maintain a healthy balance in your gut, thus supporting your immune system and gastrointestinal barrier function and integrity.*

Who Should Consider Saccharomyces boulardii - 60 CT?

Saccharomyces boulardii - 60 CT may support your health if you:

• often have unpleasant gastrointestinal symptoms, such as:
• diarrhea*
• nausea*
• constipation*
• consume a lot of processed foods in your everyday diet,*
• seek a probiotic supplement free of most common allergens due to food sensitivities*

Saccharomyces boulardii - 60 CT by Ortho Molecular Products—Effects

Saccharomyces boulardii - 60 CT by Ortho Molecular Products may:

• support gastrointestinal flora balance*
• boost immune function*
• aid gastrointestinal barrier function and integrity*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about Saccharomyces boulardii - 60 CT by Ortho Molecular Products.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Click here to view Product Info Sheet

References:

1. Buts, J. P. (2009). Twenty-five years of research on Saccharomyces boulardii trophic effects: Updates and perspectives. Digestive Diseases and Sciences, 54(1), 15-18. https://doi.org/10.1007/s10620-008-0521-5
2. McFarland, L. V. (1996). Saccharomyces boulardii is not Saccharomyces cerevisiae. Clinical Infectious Diseases, 22(1), 200-201. https://doi.org/10.1093/clinids/22.1.200
3. McFarland, L. V. (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology, 16(18), 2202-2222. https://doi.org/10.3748/wjg.v16.i18.2202
4. Zanello, G., Meurens, F., Berri, M., & Salmon, H. (2009). Saccharomyces boulardii effects on gastrointestinal diseases. Current Issues in Molecular Biology, 11(1), 47-58.
5. Buts, J. P., Corthier, G., & Delmee, M. (1993). Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. Journal of Pediatric Gastroenterology and Nutrition, 16, 419-425. https://doi.org/10.1097/00005176-199305000-00012
6. Czerucka, D., Piche, T., & Rampal, P. (2007). Review article: Yeast as probiotics—Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 26(6), 767-778. https://doi.org/10.1111/j.1365-2036.2007.03508.x
7. Gedek, B. R. (1999). Adherence of Escherichia coli serogroup O157 and the Salmonella typhimurium mutant DT104 to the surface of Saccharomyces boulardii. Mycoses, 42(4), 261-264. https://doi.org/10.1046/j.1439-0507.1999.00379.x
8. Demirel, G., Celik, I. H., Erdeve, O., Saygan, S., Dilmen, U., & Canpolat, F. E. (2013). Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants. European Journal of Pediatrics. [Epub ahead of print] https://doi.org/10.1007/s00431-013-2045-4
9. Caetano, J. A., Parames, M. T., Babo, M. J., Santos, A., et al. (1986). Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. International Journal of Immunopharmacology, 8(3), 245-259. https://doi.org/10.1016/0192-0561(86)90018-5
10. Ozkan, T. B., Sahin, E., Erdemir, G., Budak, F. (2007). Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response. Journal of International Medical Research, 35(2), 201-212. https://doi.org/10.1177/147323000703500210